Biorithm Secures $3.5 Million in Series A Funding to Advance Maternal Care Worldwide

New Funds to Fortify US Market Entry and Growth Strategy, as well as Advance Breakthrough Research Biorithm, a global women’s health medtech, has closed $3.5 million in Series A funding, co-led by Adaptive Capital Partners and SEEDS Capital. With a homegrown spirit and a global vision, Biorithm is dedicated to developing cutting-edge solutions for personalized connected maternity care. The funding will fuel Biorithm’s expansion in Southeast Asia and the United States. It also will assist the company in advancing Femom, a comprehensive obstetric remote monitoring solution, and completing clinical studies to support a 510(K) premarket submission to the US Food and Drug Administration. Complications from childbirth result in mortality for 800 women every day. Biorithm is committed to ending preventable pregnancy complications by pioneering new standards of care through protocol-based remote monitoring of maternal and fetal biometrics. Biorithm’s Femom is a patient-friendly technology that facilitates patient monitoring, accessible personalized guidance, and seamless integration of predictive analytics that helps clinicians identify early signs of complications. Julian Robinson, Chairman of Biorithm Medical Advisory Board, highlighted the significance of this technology, which will offer enhanced accessibility and improved healthcare outcomes. He further emphasized, “Biorithm will enhance care, minimize inconvenience, and reduce cost for patients and improve the effic...
Source: EMR and HIPAA - Category: Information Technology Authors: Tags: Health IT Company Healthcare IT Adaptive Capital Partners Amrish Nair Biorithm Health IT Funding Health IT Fundings Health IT Investment Julian Robinson SEEDS Capital Shi Ying Tan Kaixin Source Type: blogs